Search
Cyclophosphamide Treatment Options in Fresno, CA
A collection of 18 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the Fresno, CA. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
1 - 12 of 18
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Recruiting
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More
Gender:
ALL
Ages:
Between 5 years and 60 years
Trial Updated:
04/22/2025
Locations: City of Hope Corona, Corona, California +33 locations
Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Active Not Recruiting
This phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Kaiser Permanente-Anaheim, Anaheim, California +61 locations
Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Suspended
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
03/28/2025
Locations: Kaiser Permanente-Deer Valley Medical Center, Antioch, California +39 locations
Conditions: B Acute Lymphoblastic Leukemia
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Active Not Recruiting
This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies,... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Kaiser Permanente-Anaheim, Anaheim, California +94 locations
Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Active Not Recruiting
This phase III trial studies ibrutinib and rituximab to see how well they work compared to fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cel... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/28/2025
Locations: Kaiser Permanente-Anaheim, Anaheim, California +65 locations
Conditions: Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Active Not Recruiting
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab and combination chemotherapy and to see how well it works in treating patients with newly diagnosed stage II, stage III, or stage IV diffuse large B-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in diff... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Kaiser Permanente-Deer Valley Medical Center, Antioch, California +22 locations
Conditions: Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Active Not Recruiting
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with cancer that has spread to the lymph nodes (lymph node-positive) or cancer that has not spread to the lymph nodes but is at high risk for returning (high-risk, lymph node-negative breast cancer). Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel, work in different ways to st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2025
Locations: Kaiser Permanente-Deer Valley Medical Center, Antioch, California +63 locations
Conditions: Breast Adenocarcinoma
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Active Not Recruiting
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Kaiser Permanente-Anaheim, Anaheim, California +95 locations
Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer.
PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Alta Bates Summit Comprehensive Cancer Center, Berkeley, California +28 locations
Conditions: Breast Cancer
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor cells remaining following surgery. It is not yet known which regimen of combination chemotherapy is more effective in treating breast cancer with positive axillary lymph nodes.
PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy in treating women who... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
03/19/2024
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +15 locations
Conditions: Breast Cancer
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Completed
The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma. More specifically, the study is focused on subjects who were previously treated with bortezomib (Velcade®) or carfilzomib (Kyprolis®) and showed worsening of their myeloma while recei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +6 locations
Conditions: Multiple Myeloma
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment.
PURPOSE: This phase II trial is studying fludeoxygluc... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/16/2022
Locations: Kaiser Permanente Medical Center - Anaheim/Orange County, Anaheim, California +37 locations
Conditions: Lymphoma, Nonneoplastic Condition
1 - 12 of 18